Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD123-CD16-NK Immunotherapy for R/R AML
NCT06835140Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD123-CD16 bispecific antibody-modified NK cells in acute myeloid leukemia (AML). Primary endpoints: Objective Response Rate at 6 months, Complete Remission at 6 months and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
CD123-CD16 bispecific antibody-modified NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06835140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835140.